NAGE · Niagen Bioscience, Inc.
$3.19
-0.21 (-6.18%)
At close · Jul 23
Market Cap
$254.07M
Shares
79.64M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Robert Fried | CEO | $8,381,900 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Robert Fried | CEO | $1,212,131 |
| Ozan Pamir | CFO | $461,641 |
| Brianna Gerber | CFO | $450,969 |
| James Lee | CFO | $374,470 |
| Carlos Lopez | General Counsel | $347,637 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Robert Fried | CEO | $1,160,206 |
| Brianna Gerber | CFO | $691,588 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Robert Fried | CEO | $1,158,850 |
| Brianna Gerber | CFO | $842,384 |
| Kevin Farr | CFO | $839,537 |
| Frank Jaksch | Chairman | $482,354 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Robert Fried | CEO | $1,103,160 |
| Lisa Harrington | — | $1,037,785 |
| Frank Jaksch | Chairman | $694,559 |
| Kevin Farr | CFO | $626,429 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Robert Fried | CEO | $1,126,685 |
| Frank Jaksch | Chairman | $734,678 |
| Kevin Farr | CFO | $688,816 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Robert Fried | CEO | $1,711,894 |
| Frank Jaksch | Chairman | $636,778 |
| Kevin Farr | CFO | $621,503 |
Key facts
CIK
1386570
CUSIP
171077407
13F (30d)
18 filings
18 filers
Visit website
Investor relations